Mazdutide side effects

What the 48-week trial can—and cannot—show

The page above comes from a dose-finding study with 610 people. It tested weekly doses of 4 mg · 6 mg. The study shows what happened during that window. It may miss rare or later problems.

This page preserves 6 common reactions and 0 serious entries from that report. A missing reaction is outside this bounded record; it is not a result that the reaction cannot occur.

• Approved in China, not in the United States. FDA has approved no mazdutide product and holds no label for it. A Drugs@FDA search on 13 August 2026 found nothing under any of its four names
• At 10 milligrams in 2 milliliters, the draw for 6 mg is 1.2 mL and for 9 mg is 1.8 mL. Neither fits a 1 mL barrel, so the common habit of mixing into 2 mL does not work at this compound’s upper doses
• Nobody here has read the approved Chinese label. Every quantity on this page is a trial arm from a published paper. That is why no dosing schedule is printed as one
• Every result was measured in Chinese adults. An independent 2026 review of nine trials says longer and more varied studies are still needed. It names durability, wider populations and heart safety as the open questions
• Participants also started lighter than a US obesity trial would enroll. The average was 87.2 kg in one phase 3 trial and 94.0 kg in the other. A percentage of body weight is a percentage of the body it was measured in
• Trial doses are study information, not a recommendation
• Gut reactions were the rule rather than the exception at the highest dose. More than half the 9 mg group reported vomiting, and nearly half reported nausea
• The climb in the trials was slow. Each step lasted four weeks, and reaching 6 mg took eight weeks of lower doses first. Faster increases were not studied
• The same two doses run through the diabetes trials as through the obesity ones. So a milligram figure for this compound does not say which trial it came from, or which question it was answering
• The 9 mg figure comes from one trial with a single dose group. It did not compare 9 mg with a lower dose, so the study cannot tell us what the step up from 6 mg changes
• The dose-finding trial that chose these amounts ran 3 mg, 4.5 mg and 6 mg for 24 weeks in 248 people. The 4.5 mg arm went no further, so it has a published result and no later trial behind it
• The comparison most readers want is against semaglutide. Two phase 3 trials running exactly that comparison are registered and one of them has finished, but no result from either has been published
• Doses above 9 mg have been given only in small early trials. One gave 10 mg to eight people. Another climbed 24 people toward a 16 mg target over twenty weeks. A figure above that range has nothing behind it
• Employees of Innovent Biologics are co-authors on every trial cited here. That is ordinary for a drug company’s own program. It is also why an independent review is cited beside them
• This acts on the glucagon receptor as well as GLP-1. That is what separates it from semaglutide and tirzepatide. The second receptor is not simply extra weight loss, and what it does over years is not settled in anyone
• Anything sold under this name outside a Chinese pharmacy is not the approved product. No regulator anywhere has looked at what is in the vial

This is the one compound on this site approved somewhere and not here.

China approved mazdutide in June 2025 for weight, and in September 2025 for type 2 diabetes. It is sold there as Xinermei. That approval governs a Chinese pharmacy and nothing else.

FDA has approved no mazdutide product, and a Drugs@FDA search on 13 August 2026 found nothing under any of its four names. The drug is dispensed under supervision several thousand miles away. Anything reaching a US reader outside that is unapproved and unchecked.

No schedule is copied from the Chinese label, because nobody here has read it.